Trials / Completed
CompletedNCT01672762
A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients
Phase III Study of ASP1941 -A Phase III, Open-Label, Uncontrolled, Monotherapy Study to Assess the Long-term Safety, Tolerability and Efficacy of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 174 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate safety and efficacy of ASP1941 after 24 week administration to diabetic patients.
Detailed description
Subjects will undergo the 6-week screening period before entering the 24-week treatment period and will receive ASP1941 before breakfast during the treatment period. All subjects will be followed for 4 weeks after study treatment is discontinued.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ipragliflozin | oral |
Timeline
- Start date
- 2012-05-25
- Primary completion
- 2013-04-13
- Completion
- 2013-04-13
- First posted
- 2012-08-27
- Last updated
- 2024-11-08
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT01672762. Inclusion in this directory is not an endorsement.